D-Amphetamine sulfate

Pricing Availability   Qty
Cat.No. 2813 - D-Amphetamine sulfate | C9H13N.1/2H2SO4 | CAS No. 51-63-8
Description: Induces dopamine, 5-HT and noradrenalin release; also α7 nAChR antagonist
Alternative Names: Dextroamphetamine sulfate
Chemical Name: (+)-α-Methylphenethylamine hemisulfate salt
Purity: ≥99% (HPLC)
Datasheet
Citations (5)
Reviews
Literature

Biological Activity

CNS stimulant. Targets monoamine transporters to elevate synaptic levels of noradrenalin, dopamine and serotonin. Also α7 nAChR antagonist.

Technical Data

M. Wt 184.25
Formula C9H13N.1/2H2SO4
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 51-63-8
PubChem ID 5825
InChI Key PYHRZPFZZDCOPH-QXGOIDDHSA-N
Smiles N[C@@H](C)CC1=CC=CC=C1.N[C@@H](C)CC2=CC=CC=C2.OS(O)(=O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 18.43 100

Preparing Stock Solutions

The following data is based on the product molecular weight 184.25. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 5.43 mL 27.14 mL 54.27 mL
5 mM 1.09 mL 5.43 mL 10.85 mL
10 mM 0.54 mL 2.71 mL 5.43 mL
50 mM 0.11 mL 0.54 mL 1.09 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Barr et al (1999) Effects of withdrawal from an escalating dose schedule of d-Amphetamine on sexual behavior in the male rat. Pharmacol.Biochem.Behav. 64 597 PMID: 10548277

Cartmell et al (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-Amphetamine motor behaviors in rats. J.Pharmacol.Exp.Ther. 291 161 PMID: 10490900

Rothman and Baumann (2006) Balance between dopamine and serotonin release modulates behavioral effects of Amphetamine-type drugs. Ann.N.Y.Acad.Sci. 1074 245 PMID: 17105921

Garton et al (2018) Amphetamine enantiomers inhibit homomeric a7 nicotinic receptor through a competitive mechanism and within the intoxication levels in humans. Neuropharmacology PMID: 30359640


If you know of a relevant reference for D-Amphetamine sulfate, please let us know.

Keywords: D-Amphetamine sulfate, D-Amphetamine sulfate supplier, Induces, 5-HT, dopamine, noradrenaline, release, Serotonin, 5-Hydroxytryptamine, amphetamine, Dextroamphetamine, sulfate, Dopaminergic-Related, Adrenergic, Related, Compounds, 5-HT-Related, 5-HT3, Receptors, Nicotinic, (a7), 2813, Tocris Bioscience

5 Citations for D-Amphetamine sulfate

Citations are publications that use Tocris products. Selected citations for D-Amphetamine sulfate include:

Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. PLoS One 40 766 PMID: 25249058

Beerepoot et al (2016) Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem 291 22053 PMID: 27555326

Rennekamp et al (2016) σ1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol 12 552 PMID: 27239788

Soda et al (2013) DISC1-ATF4 transcriptional repression complex: dual regulation of the cAMP-PDE4 cascade by DISC1. Mol Psychiatry 18 898 PMID: 23587879

Ribeiro et al (2014) Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease. Neuropsychopharmacology 23 2030 PMID: 24282028


Do you know of a great paper that uses D-Amphetamine sulfate from Tocris? Please let us know.

Reviews for D-Amphetamine sulfate

There are currently no reviews for this product. Be the first to review D-Amphetamine sulfate and earn rewards!

Have you used D-Amphetamine sulfate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.